Skip to main content
Journal cover image

NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.

Publication ,  Journal Article
Moul, JW; Sarno, MJ; McDermed, JE; Triebell, MT; Reynolds, MA
Published in: Urology
December 2014

OBJECTIVE: To assess whether NADiA ProsVue prostate-specific antigen slope, a prognostic biomarker for identifying men at a reduced risk of clinically recurrent prostate cancer after radical prostatectomy, is prognostic for prostate cancer--specific mortality (PCSM) and other outcomes. MATERIALS AND METHODS: We examined long-term outcome in the cohort of 304 men selected for the ProsVue 510(k) clinical trial. We assessed the prognostic value of a ProsVue result ≤ 2.0 pg/mL/mo and pathologic risk stratified by the Cancer of the Prostate Risk Assessment Postsurgical nomogram for a reduced risk of prostate cancer--specific survival. We also assessed its value for predicting clinical outcome in men given salvage treatment for biochemical recurrence. Efficacy was assessed using univariate and multivariate Cox regression and the Kaplan-Meier analyses. RESULTS: Median (interquartile range) overall survival for the groups of men with a ProsVue slope result ≤ 2.0 and >2.0 pg/mL/mo were 11.0 (9.4-12.9) and 9.2 (4.9-11.6) years, respectively. The ProsVue univariate hazard ratio (95% confidence interval) for PCSM was 20.6 (6.8-62.7), with P <.0001 for a ProsVue result >2.0 pg/mL/mo vs a result ≤ 2.0 pg/mL/mo. The multivariate hazard ratio of ProsVue adjusted by Cancer of the Prostate Risk Assessment Postsurgical nomogram remained significant (16.7 [4.7-58.6]; P <.0001). The inverse of the hazard ratio translates to a 94.0% risk reduction for PCSM for men with a ProsVue result ≤ 2.0 pg/mL/mo. Salvage treatment for biochemical recurrence did not significantly reduce the hazard of clinical recurrence or PCSM; however, this is based on only 18 events. CONCLUSION: A NADiA ProsVue slope result ≤ 2.0 pg/mL/mo was prognostic for a reduced risk of PCSM in men after radical prostatectomy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Urology

DOI

EISSN

1527-9995

Publication Date

December 2014

Volume

84

Issue

6

Start / End Page

1427 / 1432

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Treatment Outcome
  • Survival Analysis
  • Risk Assessment
  • Prostatic Neoplasms
  • Prostatectomy
  • Prostate-Specific Antigen
  • Prospective Studies
  • Proportional Hazards Models
  • Neoplasm Recurrence, Local
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Moul, J. W., Sarno, M. J., McDermed, J. E., Triebell, M. T., & Reynolds, M. A. (2014). NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy. Urology, 84(6), 1427–1432. https://doi.org/10.1016/j.urology.2014.07.059
Moul, Judd W., Mark J. Sarno, Jonathan E. McDermed, Melissa T. Triebell, and Mark A. Reynolds. “NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.Urology 84, no. 6 (December 2014): 1427–32. https://doi.org/10.1016/j.urology.2014.07.059.
Moul JW, Sarno MJ, McDermed JE, Triebell MT, Reynolds MA. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy. Urology. 2014 Dec;84(6):1427–32.
Moul, Judd W., et al. “NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.Urology, vol. 84, no. 6, Dec. 2014, pp. 1427–32. Pubmed, doi:10.1016/j.urology.2014.07.059.
Moul JW, Sarno MJ, McDermed JE, Triebell MT, Reynolds MA. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy. Urology. 2014 Dec;84(6):1427–1432.
Journal cover image

Published In

Urology

DOI

EISSN

1527-9995

Publication Date

December 2014

Volume

84

Issue

6

Start / End Page

1427 / 1432

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Treatment Outcome
  • Survival Analysis
  • Risk Assessment
  • Prostatic Neoplasms
  • Prostatectomy
  • Prostate-Specific Antigen
  • Prospective Studies
  • Proportional Hazards Models
  • Neoplasm Recurrence, Local